Integrated BioPharma, Inc.

OTCPK:INBP Stock Report

Market Cap: US$9.6m

Integrated BioPharma Past Earnings Performance

Past criteria checks 2/6

Integrated BioPharma's earnings have been declining at an average annual rate of -30.4%, while the Personal Products industry saw earnings growing at 9.3% annually. Revenues have been declining at an average rate of 1.9% per year. Integrated BioPharma's return on equity is 2.2%, and it has net margins of 0.8%.

Key information

-30.4%

Earnings growth rate

-30.5%

EPS growth rate

Personal Products Industry Growth20.9%
Revenue growth rate-1.9%
Return on equity2.2%
Net Margin0.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Integrated BioPharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:INBP Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2451040
30 Jun 2450040
31 Mar 2451040
31 Dec 2351040
30 Sep 2351040
30 Jun 2351040
31 Mar 2351140
31 Dec 2253240
30 Sep 2256340
30 Jun 2256440
31 Mar 2260740
31 Dec 2161740
30 Sep 2161740
30 Jun 2164840
31 Mar 2160540
31 Dec 2057540
30 Sep 2057530
30 Jun 2053430
31 Mar 2053340
31 Dec 1953340
30 Sep 1951240
30 Jun 1950240
31 Mar 1949230
31 Dec 1845230
30 Sep 1844130
30 Jun 1844130
31 Mar 1842130
31 Dec 1742130
30 Sep 1744230
30 Jun 1747230
31 Mar 1747230
31 Dec 1647130
30 Sep 1645130
30 Jun 1642130
31 Mar 1640030
31 Dec 1538030
30 Sep 1538130
30 Jun 1537130
31 Mar 1537130
31 Dec 1435030
30 Sep 1433030
30 Jun 1434030
31 Mar 1435140
31 Dec 1336140

Quality Earnings: INBP has high quality earnings.

Growing Profit Margin: INBP became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: INBP's earnings have declined by 30.4% per year over the past 5 years.

Accelerating Growth: INBP has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: INBP has become profitable in the last year, making it difficult to compare its past year earnings growth to the Personal Products industry (-5.2%).


Return on Equity

High ROE: INBP's Return on Equity (2.2%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 05:54
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Integrated BioPharma, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution